Mangold Insight publishes initial analysis of Brighter
Brighter AB (publ) ("Brighter" or "the Company") announces today that Mangold Insight will begin monitoring Brighter and publishes an initial analysis.
The analysis is based on the size of the global diabetes market, which is growing by 6.1 percent per year (CAGR), and the Company's focus on digital diabetes care, where the technology developed by the Company is aiming to improve efficiency within diabetes treatment. Identified challenges are that the Company must succeed with the commercialization in 2022 and thereby establish itself and gain market shares.
Mangold Insight believes that Brighter's solutions and the several collaboration agreements with various partners around the world provide a good basis for the Company to succeed. Especially since interest in digital healthcare solutions is considered to be sky-high, and an increasing number of investors notice the added value that alternative players bring to patients and healthcare.
Link to the analysis (in Swedish) here
For further information, please contact:
Brighter’s Certified Adviser is Eminova Fondkommission AB,
+46 (0)8 – 684 211 10, firstname.lastname@example.org, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision of facilitating the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter’s quality management system is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on the Nasdaq First North Growth Market/BRIG.